Yunyuan Huang

central china normal university

H指数:13

被引数:379

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Covalent allosteric inhibition of AARS1 lactyltransferase

AARS1乳酰基转移酶的共价别构抑制

Nature Communications

IF15.7

2026-08-170

Discovery and biological evaluation of HS13 as a novel covalent ligand targeting the NSD2-PWWP1 domain

HS13作为靶向NSD2-PWWP1域的新型共价配体的发现与生物活性评价

BIOORGANIC & MEDICINAL CHEMISTRY

IF3

2026-07-010

PRE

Discovery of a quinoline-based senomorphic agent for the treatment of chronic kidney disease

喹啉基类长寿素药物发现及其在慢性肾病治疗中的应用

European Journal of Medicinal Chemistry

IF5.9

2026-07-010

PRE

Identification of Novel Covalent Ligands that Disrupt Acetyl-Lysine Binding to the SETDB1 Tudor Domain

新型共价配体对SETDB1 Tudor结构域中乙酰化赖氨酸结合的干扰鉴定

Biochemical and Biophysical Research Communications

IF2.2

2026-04-210

PRE

Structure-based design of the approved drug zafirlukast identifies HLC40 as a potent WDR5 WIN-site inhibitor with antitumor efficacy

基于已批准药物扎非鲁kast的结构设计确定了HLC40是一种具有抗肿瘤活性的强效WDR5 WIN位点抑制剂

Bioorganic Chemistry

IF4.7

2026-04-150

PRE

Correction to “Discovery of Non-antibacterial Enrofloxacin Derivatives with Emerging Antiaging Effects through Drug Repurposing and Secondary Development”

对“通过药物重定位和二次开发发现具有新兴抗衰老作用的无抗菌性恩诺沙星衍生物”的更正

Journal of Medicinal Chemistry

IF6.8

2026-03-020

PRE

Discovery of Non-antibacterial Enrofloxacin Derivatives with Emerging Antiaging Effects through Drug Repurposing and Secondary Development

通过药物重定位和二次开发发现具有新兴抗衰老作用的非抗菌性恩诺沙星衍生物

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2025-05-090

PRE

Glibenclamide targets MDH2 to relieve aging phenotypes through metabolism-regulated epigenetic modification

格列本脲靶向MDH2，通过代谢调控的表观遗传修饰缓解衰老表型。

SIGNAL TRANSDUCTION AND TARGETED THERAPY

IF52.7

2025-02-170

Design of the Inhibitors for Pseudorabies Virus Replication by Reinforcement Learning from HSV-1 DNA Polymerase Inhibitors

ACS OMEGA

IF4.3

2025-01-231

OAAI

Inhibitors targeting the PWWP domain-containing proteins

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2024-12-011

PRE

Novel Combination Therapy for Heart Failure: Trimebutine-Methoxsalen Identified through Synergistic Network Virtual Screening and Experimental Validation

JOURNAL OF CHEMICAL INFORMATION AND MODELING

IF5.3

2024-09-110

PRE

A Senomorphlytic Three-Drug Combination Discovered in Salsola collina for Delaying Aging Phenotypes and Extending Healthspan

ADVANCED SCIENCE

IF14.1

2024-07-291

OAAI

Advances in inhibitor development targeting the PWWP domain

TRENDS IN PHARMACOLOGICAL SCIENCES

IF19.9

2024-03-014

PRE

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-04-015

OAAI

Photoactivatable senolysis with single-cell resolution delays aging

NATURE AGING

IF19.4

2023-02-0236

PRE

N-Acylamino Saccharin as an Emerging Cysteine-Directed Covalent Warhead and Its Application in the Identification of Novel FBPase Inhibitors toward Glucose Reduction

JOURNAL OF MEDICINAL CHEMISTRY

IF6.8

2022-07-058

PRE

Discovery of novel dual RAGE/SERT inhibitors for the potential treatment of the comorbidity of Alzheimer's disease and depression

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

IF5.9

2022-06-0112

PRE

Identification of Guaifenesin-Andrographolide as a Novel Combinatorial Drug Therapy for Epilepsy Using Network Virtual Screening and Experimental Validation

ACS CHEMICAL NEUROSCIENCE

IF3.9

2022-03-252

PRE

Specific tracking of monoamine oxidase A in heart failure models by a far-red fluorescent probe with an ultra large Stokes shift

CHINESE CHEMICAL LETTERS

IF8.9

2022-03-0116

PRE

Anti-aging effects of chlorpropamide depend on mitochondrial complex-II and the production of mitochondrial reactive oxygen species

ACTA PHARMACEUTICA SINICA B

IF14.6

2022-02-0111

OAAI

Yunyuan Huang

个人简介

教育背景

工作经历

荣誉奖项

研究方向